Lab Secrets for Stratification and Prognoses of Leukemia and Multiple Myeloma using Next-Generation Sequencing (NGS): Strategies to Leverage NGS-based minimal residual disease (MRD) in Multiple Myeloma (MM) and Acute Lymphoblastic Leukemia (ALL)

De Brouwer, W. (Invited speaker)
Van der Straeten, J. (Contributor)
Van Riet, I. (Contributor)
Bakkus, M. (Contributor)

Activity: Talk or presentation › Talk at a public lecture/debate

Description

For decades, pediatric ALLs have been stratified based on the presence of MRD. Likewise, in multiple myeloma, the absence of detectable levels of MRD has demonstrated a clear correlation with longer overall survival. Currently, quantitative allele-specific oligonucleotide (qASO)-PCR is the standard molecular method for MRD detection in these hematologic malignant tumors. However, this technique has some drawbacks that can be overcome by NGS. In this webinar, Dr. Wouter De Brouwer will discuss characteristics, considerations and strategies identified during his laboratory’s NGS MRD validation.

Period	24 Feb 2022
Held at	Association for Molecular Pathology (AMP), United States
Degree of Recognition	International

Lab Secrets for Stratification and Prognoses of Leukemia and Multiple Myeloma using Next-Generation Sequencing (NGS): Strategies to Leverage NGS-based minimal residual disease (MRD) in Multiple Myeloma (MM) and Acute Lymphoblastic Leukemia (ALL)

Description

Related content

Research output

Validation of a PCR-based next-generation sequencing approach for the detection and quantification of minimal residual disease in acute lymphoblastic leukemia and multiple myeloma using gBlocks as calibrators